LLY 2026 Q3

Eli Lilly (LLY) reports earnings:

Profit: $8.38 vs. $6.31 = +33%
Profit Est: $8.82 vs. $6.31 = +40%
Missed the street by $0.44
Revenue: +48%
Revenue Est: +31%

Research Library

Mounjaro and Zepbound are Driving Eli Lilly’s (LLY) Revenue and Profits Higher

August 24, 2026

Eli Lilly’s (LLY) Mounjaro and Zepbound are blockbusters in the obesity drug market. Now Foundayo is making waves in a pill form. Read More >>

LLY 2026 Q3

August 5, 2026

Eli Lilly (LLY) reports earnings:

Profit: $8.38 vs. $6.31 = +33%
Profit Est: $8.82 vs. $6.31 = +40%
Missed the street by $0.44
Revenue: +48%
Revenue Est: +31% Read More >>

U.S. Stocks End Lower as Tech Selloff Weighs on Markets

July 1, 2026

Wall Street starts second half of 2026 on a weak note. Eli Lilly’s (LLY) oral weight loss drug, Foundayo, could become a big catalyst. Read More >>

Eli Lilly’s (LLY) Oral Weight Loss Drug, Foundayo, Could Become a Big Catalyst

June 19, 2026

Eli Lilly's (LLY) oral weight loss drug Foundayo expands the market beyond injectables & could be a blockbuster as people want pills. Read More >>

LLY 2026 Q2

April 30, 2026

Eli Lilly (LLY) reports earnings:

Profit: $8.55 vs. $3.34 = +156%
Profit Est: $7.25 vs. $3.34 = +117%
Beat the street by $1.30
Revenue: +56%
Revenue Est: +37% Read More >>

S&P 500, NASDAQ Close Higher on News of a Two-Week Ceasefire

April 8, 2026

Stocks ends mixed on Tuesday on ceasefire hopes. Eli Lilly (LLY) has a weight loss drug pipeline to drive future growth. Read More >>

Eli Lilly (LLY) has a Weight Loss Drug Pipeline to Drive Growth for Years to Come

April 7, 2026

Eli Lilly (LLY) has two blockbusters with Mounjaro and Zepbound. It also has new drugs coming to drive growth for years to come. Read More >>

LLY 2026 Q1

February 4, 2026

Eli Lilly (LLY) reports earnings:

Profit: $7.54 vs. $5.32 = +42%
Profit Est: $7.07 vs. $5.32 = +33%
Beat the street by $0.47
Revenue: +43%
Revenue Est: +31% Read More >>

Stocks Dip as Investors React to Inflation Data

January 13, 2026

Stocks fell on Tuesday as inflation eases. Mounjaro and Zepbound drive Eli Lilly (LLY) stock to an All-Time High. Read More >>

Mounjaro and Zepbound Drive Eli Lilly (LLY) Stock to an All-Time High

January 8, 2026

Eli Lilly (LLY) stock reaches an All-Time High in late November, fueled by strong performances from Mounjaro and Zepbound. Read More >>

Email
Password
	Remember me
	Forgot Password

About The Author

Trisha Concepcion

Not a member? Sign up here for $25 a month.

About The Author

Trisha Concepcion

Enter your email address and password below.

Not a member? Sign up here for $25 a month.